Literature DB >> 16356025

Management of Landau-Kleffner syndrome.

Mohamad A Mikati1, Alhan N Shamseddine.   

Abstract

Landau-Kleffner syndrome (LKS) is an acquired epileptic aphasia disorder in which children, usually 3-8 years of age who have developed age-appropriate speech, experience language regression with verbal auditory agnosia, abnormal epileptiform activity, behavioral disturbances, and sometimes overt seizures. There are no controlled clinical trials investigating the therapeutic options for LKS. Only open-label data are available. Early diagnosis and initiation of prompt medical treatment appear to be important to achieving better long-term prognosis.Several antiepileptic drugs have been reported to be beneficial in treating this syndrome. These include valproic acid (valproate sodium), diazepam, ethosuximide, clobazam, and clonazepam. Reports on the efficacy of lamotrigine, sultiame, felbamate, nicardipine, vigabatrin, levetiracetam, vagal nerve stimulation, and a ketogenic diet are few and more experience is needed. Carbamazepine and possibly phenobarbital and phenytoin have been reported to occasionally exacerbate the syndrome. As initial therapy, valproic acid or diazepam is often empirically chosen. Subsequently, other antiepileptic drugs, corticosteroids, or intravenous immunoglobulin (IVIG) therapy are often used. Corticosteroid therapy should probably not be delayed more than 1-2 months after the initial diagnosis. Various corticosteroid regimens including oral prednisone and, recently, high doses of intravenous pulse corticosteroids, as well as corticotropin (adrenocorticotropic hormone) have been reported to be effective in LKS. Oral corticosteroids are used more often and usually need to be maintained for a long period of time to prevent relapses. The use of IVIG has been associated with an initial dramatic response in only a few patients. In our experience, a long-term worthwhile improvement has been noted in only 2 of 11 patients. These two patients had an immediate response to IVIG initially and after relapses before eventually achieving a long-term sustained remission. Surgical treatment by multiple subpial transection, which is reserved for patients who have not responded to multiple medical therapies, has been followed in selected cases by a marked improvement in language skills and behavior. However, a widely accepted consensus about suitable candidates for this surgery and about its efficacy is still lacking. Speech therapy, including sign language, and a number of classroom and behavioral interventions are helpful in managing LKS, and should be used in all patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356025     DOI: 10.2165/00148581-200507060-00006

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  51 in total

1.  Efficacy of intravenous immunoglobulin in Landau-Kleffner syndrome.

Authors:  Mohamad A Mikati; Raya Saab; Michel N Fayad; Roula N Choueiri
Journal:  Pediatr Neurol       Date:  2002-04       Impact factor: 3.372

2.  The Landau-Kleffner syndrome or 'acquired aphasia with convulsive disorder'. Long-term follow-up of six children and a review of the recent literature.

Authors:  P F Paquier; H R Van Dongen; C B Loonen
Journal:  Arch Neurol       Date:  1992-04

3.  Multiple subpial transection in Landau-Kleffner syndrome.

Authors:  K Irwin; V Birch; J Lees; C Polkey; G Alarcon; C Binnie; M Smedley; G Baird; R O Robinson
Journal:  Dev Med Child Neurol       Date:  2001-04       Impact factor: 5.449

4.  A case of acquired aphasia and convulsive disorder: some linguistic aspects of recovery and breakdown.

Authors:  W M van de Sandt-Koenderman; I A Smit; H R van Dongen; J B van Hest
Journal:  Brain Lang       Date:  1984-01       Impact factor: 2.381

5.  Acquired aphasia of childhood with epilepsy: the Landau-Kleffner syndrome.

Authors:  G J Hankey; S S Gubbay
Journal:  Clin Exp Neurol       Date:  1987

6.  Landau-Kleffner syndrome: a pharmacologic study of five cases.

Authors:  C Marescaux; E Hirsch; S Finck; P Maquet; E Schlumberger; F Sellal; M N Metz-Lutz; Y Alembik; E Salmon; G Franck
Journal:  Epilepsia       Date:  1990 Nov-Dec       Impact factor: 5.864

7.  Treatment of Childhood Idiopathic Language Deterioration with Valproate.

Authors:  Gregory L. Holmes; James J. Riviello
Journal:  Epilepsy Behav       Date:  2001-06       Impact factor: 2.937

8.  A case of Landau-Kleffner syndrome secondary to inflammatory demyelinating disease.

Authors:  T Perniola; L Margari; M Buttiglione; C Andreula; I L Simone; R Santostasi
Journal:  Epilepsia       Date:  1993 May-Jun       Impact factor: 5.864

9.  Acquired epileptic aphasia: neuropsychologic follow-up of 12 patients.

Authors:  A M Soprano; E F Garcia; R Caraballo; N Fejerman
Journal:  Pediatr Neurol       Date:  1994-10       Impact factor: 3.372

10.  Landau-Kleffner syndrome responsive to levetiracetam.

Authors:  Eric H Kossoff; Dana Boatman; John M Freeman
Journal:  Epilepsy Behav       Date:  2003-10       Impact factor: 2.937

View more
  4 in total

Review 1.  The promise of futility trials in neurological diseases.

Authors:  Marcus W Koch; Lawrence Korngut; David G Patry; Yahya Agha-Khani; Christopher White; Justyna R Sarna; Michael Yeung; V Wee Yong; Daniel Y C Heng; Gary Cutter; Luanne Metz
Journal:  Nat Rev Neurol       Date:  2015-03-17       Impact factor: 42.937

Review 2.  What is more harmful, seizures or epileptic EEG abnormalities? Is there any clinical data?

Authors:  Gregory L Holmes
Journal:  Epileptic Disord       Date:  2014-10       Impact factor: 1.819

Review 3.  Selected rare paediatric communication neurological disorders.

Authors:  Blanka Klimova; Martin Valis; Jakub Hort; Kamil Kuca
Journal:  J Appl Biomed       Date:  2018-11-23       Impact factor: 1.797

4.  Continuous Spikes and Waves during Sleep: Electroclinical Presentation and Suggestions for Management.

Authors:  Iván Sánchez Fernández; Kevin E Chapman; Jurriaan M Peters; Chellamani Harini; Alexander Rotenberg; Tobias Loddenkemper
Journal:  Epilepsy Res Treat       Date:  2013-08-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.